“…About half of survivors continue to require immunoglobulin replacement, 62% of whom have IL2RG deficiency, for which B-cell reconstitution is known to be challenging. 12 More than 80% of patients with RAG1 and RAG2 deficiency also continue to require immunoglobulin replacement therapy. However, patients with IL7R (94%), ADA (78%), and CD3 component deficiencies (100%) develop normal B-cell function and are able to discontinue immunoglobulin infusions.…”